Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Eli Lilly (LLY) is following the right approach for the obesity drugs business as it explores multiple ways to address the balance between demand and supply, according to Truist Securities. The ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock-full of ...

Novo is up 19% so far this year, while Eli Lilly has gained 33%. The iShares U.S. Pharmaceuticals ETF IHE , an exchange traded fund that tracks U.S. pharma companies, is up 12.5% in 2024.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Shares of Eli Lilly And Co (NYSE: LLY) were climbing during Friday's trading session. The stock has been under pressure for the past three months, due to macro uncertainties and not ...

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050.

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050.